Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,395
datasets available to search
ShareScore release 0.7.1
Dataset results
1,395 results for “Tumor immunity”
Akt inhibition with MK-2206 is associated with favorable immune profile changes within the tumor microenvironment of hormone receptor positive, HER2 negative breast cancer
GEO Series GSE150512. Homo sapiens. 20 samples. Type: Expression profiling by array.
Mutant IDH1 inhibition induces dsDNA sensing to activate tumor immunity [human WGBS]
GEO Series GSE265854. Homo sapiens. 12 samples. Type: Methylation profiling by high throughput sequencing.
Integration of tumor-specific dendritic cell and antibody therapy within tumor drives innate and adaptive anti-cancer immunity [Metabolic_Pathways_NanoString]
GEO Series GSE302735. Mus musculus. 18 samples. Type: Expression profiling by array.
Synergistic immunochemotherapy exerts efficiently anti-hepatocellular carcinoma effect to induce SAMD4B-APOA2 axis for inhibition of tumor immune evasion [NM-seq]
GEO Series GSE223622. Homo sapiens. 12 samples. Type: Other.
Mutant IDH1 inhibition induces dsDNA sensing to activate tumor immunity [RRBS]
GEO Series GSE264722. Homo sapiens. 15 samples. Type: Methylation profiling by high throughput sequencing.
Tumor-intrinsic P2RY6 signaling promotes prostaglandin E2 production to suppress anti-tumor immunity [ATAC]
GEO Series GSE242928. Mus musculus. 4 samples. Type: Genome binding/occupancy profiling by high throughput sequencing.
Immune-stimulating antibody conjugates elicit robust myeloid activation and durable anti-tumor immunity
GEO Series GSE157870. Mus musculus. 40 samples. Type: Other; Expression profiling by array.
A novel CRISPR/Cas9 screening platform identifies an IRF1-SOCS1-mediated negative feedback loop that limits CXCL9 expression and anti-tumor immunity (AT3 ATAC-Seq)
GEO Series GSE237967. Mus musculus. 8 samples. Type: Genome binding/occupancy profiling by high throughput sequencing.
Irinotecan activates anti-tumor immunity in HCT116 tumor cells
GEO Series GSE245809. Homo sapiens. 6 samples. Type: Expression profiling by high throughput sequencing.
Dataset related to article "Activation of the VEGFC/VEGFR3 Pathway Induces Tumor Immune Escape in Colorectal Cancer."
<p>Colorectal cancer is a major cause of cancer-related death in Western countries and is associated with increased numbers of lymphatic vessels (LV) and tumor-associated macrophages (TAM). The VEGFC/VEGFR3 pathway is regarded as the principal inducer of lymphangiogenesis and it contributes to metastases; however, no data are available regarding its role during primary colorectal cancer development. We found that both VEGFC and VEGFR3 were upregulated in human nonmetastatic colorectal cancer, with VEGFR3 expressed on both LVs and TAMs. With the use of three different preclinical models of colorectal cancer, we also discovered that the VEGFC/VEGFR3 axis can shape both lymphatic endothelial cells and TAMs to synergistically inhibit antitumor immunity and promote primary colorectal cancer growth. Therefore, VEGFR3-directed therapy could be envisioned for the treatment of nonmetastatic colorectal cancer. SIGNIFICANCE: The prolymphangiogenic factor VEGFC is abundant in colorectal cancer and activates VEGFR3 present on cancer-associated macrophages and lymphatic vessels; activation of VEGFR3 signaling fosters cancer immune escape, resulting in enhanced tumor growth.</p>
Dataset related to article "Intratumoral combination therapy with poly(I:C) and resiquimod synergistically triggers tumor-associated macrophages for effective systemic antitumoral immunity "
<p>This record contains raw data related to article “Intratumoral combination therapy with poly(I:C) and resiquimod synergistically triggers tumor-associated macrophages for effective systemic antitumoral immunity"</p> <p><strong>Background: </strong> Tumor-associated macrophages (TAMs) play a key immunosuppressive role that limits the ability of the immune system to fight cancer and hinder the antitumoral efficacy of most treatments currently applied in the clinic. Previous studies have evaluated the antitumoral immune response triggered by (TLR) agonists, such as poly(I:C), imiquimod (R837) or resiquimod (R848) as monotherapies; however, their combination for the treatment of cancer has not been explored. This study investigates the antitumoral efficacy and the macrophage reprogramming triggered by poly(I:C) combined with R848 or with R837, versus single treatments.</p> <p><strong>Methods: </strong> TLR agonist treatments were evaluated in vitro for toxicity and immunostimulatory activity by Alamar Blue, ELISA and flow cytometry using primary human and murine M-CSF-differentiated macrophages. Cytotoxic activity of TLR-treated macrophages toward cancer cells was evaluated with an in vitro functional assay by flow cytometry. For in vivo experiments, the CMT167 lung cancer model and the MN/MCA1 fibrosarcoma model metastasizing to lungs were used; tumor-infiltrating leukocytes were evaluated by flow cytometry, RT-qPCR, multispectral immunophenotyping, quantitative proteomic experiments, and protein-protein interaction analysis.</p> <p><strong>Results: </strong> Results demonstrated the higher efficacy of poly(I:C) combined with R848 versus single treatments or combined with R837 to polarize macrophages toward M1-like antitumor effectors in vitro. In vivo, the intratumoral synergistic combination of poly(I:C)+R848 significantly prevented tumor growth and metastasis in lung cancer and fibrosarcoma immunocompetent murine models. Regressing tumors showed increased infiltration of macrophages with a higher M1:M2 ratio, recruitment of CD4<sup>+</sup> and CD8<sup>+</sup> T cells, accompanied by a reduction of immunosuppressive CD206<sup>+</sup> TAMs and FOXP3<sup>+</sup>/CD4<sup>+</sup> T cells. The depletion of both CD4<sup>+</sup> and CD8<sup>+</sup> T cells resulted in complete loss of treatment efficacy. Treated mice acquired systemic antitumoral response and resistance to tumor rechallenge mediated by boosted macrophage cytotoxic activity and T-cell proliferation. Proteomic experiments validate the superior activation of innate immunity by poly(I:C)+R848 combination versus single treatments or poly(I:C)+R837, and protein-protein-interaction network analysis reveal the key activation of the STAT1 pathway.</p> <p><strong>Discussion: </strong> These findings demonstrate the antitumor immune responses mediated by macrophage activation on local administration of poly(I:C)+R848 combination and support the intratumoral application of this therapy to patients with solid tumors in the clinic.</p>
Dataset related to article "Tumor heterogeneity, hypoxia, and immune markers in surgically resected non-small-cell lung cancer"
<p>This record contains raw data related to article "Tumor heterogeneity, hypoxia, and immune markers in surgically resected non-small-cell lung cancer"</p> <p>OBJECTIVES:</p> <p>This study aimed to determine the prognostic role of textural features and their association with metabolic parameters, hypoxia, and cancer-related immune markers in non-small-cell lung cancer (NSCLC) patients.</p> <p>PATIENTS AND METHODS:</p> <p>The trial was registered at http://www.clinicaltrials.gov (<a href="http://clinicaltrials.gov/show/NCT02519062">NCT02519062</a>). From January 2010 to May 2014, 44 patients (male : female=33 : 11; median age: 69.5 years), referred to our Institution for NSCLC resection, were enrolled. Tumor specimens were assessed for HIF-1α, CD68-TAMs, CD8-TILs, PD-1-TILs, and PD-L1 expressions. All patients underwent fluorine-18-fluorodeoxyglucose (F-FDG) PET before surgery. Semiquantitative parameters included maximum standardized uptake value (SUVmax), SUVpeak, SUVmean, metabolic tumor volume, and total lesion glycolysis, whereas for heterogeneity, we considered tumor sphericity, skewness, kurtosis, entropy, and energy. Parameters were correlated with disease-free survival (DFS) considering a median follow-up of 22.7 months.</p> <p>RESULTS:</p> <p>SUVmax (cutoff: 7.9; P=0.015), SUVpeak (cutoff: 6.7; P=0.013), SUVmean (cutoff: 5.5; P=0.028), metabolic tumor volume (cutoff: 3.6 cm; P=0.027), and entropy (cutoff: 1.89; P=0.045) showed a statistically significant association with DFS. Also, a high expression of cytoplasmic HIF-1α (score 3) was associated with DFS (hazard ratio: 0.09; P=0.003). All F-FDG PET variables differed significantly in tumors with high or low entropy (≤1.89). Also, a significantly higher level of mean CD8-TILs was observed in tumors with higher entropy (P=0.041).Using identified prognostic factors, we developed a scoring system, which was confirmed to be associated with DFS (P<0.004). On receiver operating characteristics analysis, a score above 3 was defined as the optimal cutoff point.</p> <p>CONCLUSION:</p> <p>Tumor heterogeneity, metabolic parameters, and high expression of hypoxia were found to be prognostic factors in NSCLC patients who were candidates for surgery. Higher levels of entropy appear to be associated with increased density of CD8-TILs. The combination of investigated prognostic factors enabled the development of a potential scoring system associated with DFS</p>
The epitranscriptional factor PCIF1 orchestrates CD8+ T cell ferroptosis and activation to govern anti-tumor immunity
GEO Series GSE254597. Mus musculus. 8 samples. Type: Other.
Annexin-A1-mediated regulation of the efferocytosis in tumor-associated macrophage promotes anti-tumor immune response by activating the cGAS/STING pathway in pancreatic cancer
GEO Series GSE255146. Mus musculus. 6 samples. Type: Expression profiling by high throughput sequencing.
Caloric Restriction Triggers Anti-tumor Immunity via a Mechanism Involving NK Cells and Transcription Factor Eomesdermin
GEO Series GSE121488. Mus musculus. 22 samples. Type: Expression profiling by high throughput sequencing; Genome binding/occupancy profiling by high throughput sequencing.
Atg7 deficiency induces a microbiome-influenced immune response and suppresses tumor growth to inhibit intestinal tumorigenesis
GEO Series GSE56337. Mus musculus. 6 samples. Type: Expression profiling by array.
Bacterial immunotherapy leveraging IL-10R hysteresis for both phagocytosis evasion and tumor immunity revitalization [CUT&Tag]
GEO Series GSE283696. Mus musculus. 33 samples. Type: Genome binding/occupancy profiling by high throughput sequencing.
Bacterial immunotherapy leveraging IL-10R hysteresis for both phagocytosis evasion and tumor immunity revitalization [ATACseq]
GEO Series GSE283695. Mus musculus. 11 samples. Type: Genome binding/occupancy profiling by high throughput sequencing.
The epitranscriptional factor PCIF1 orchestrates CD8+ T cell ferroptosis and activation to govern anti-tumor immunity
GEO Series GSE254353. Mus musculus. 4 samples. Type: Expression profiling by high throughput sequencing.
Epigenetic checkpoint regulates anti-tumor immunity of CD4 T cell in Hepatocellular carcinoma
GEO Series GSE239507. Homo sapiens. 2 samples. Type: Other.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.